Literature DB >> 29262794

Risk factors for mortality among patients admitted with upper gastrointestinal bleeding at a tertiary hospital: a prospective cohort study.

Sibtain M Moledina1, Ewaldo Komba2.   

Abstract

BACKGROUND: Upper gastrointestinal bleeding (UGIB) is a common gastrointestinal emergency, which is potentially fatal. Proper management of UGIB requires risk-stratification of patients which can guide the type and aggressiveness of management. The aim of this was study was identify the causes of UGIB and factors that increase the risk of mortality in these patients.
METHODS: This was a prospective cohort study conducted over a period of seven months at a tertiary hospital. Adults admitted with UGIB were included in the study. Demographic data, laboratory parameters and endoscopic findings were recorded. Patients were then followed up for 60 days to identify the occurrence of mortality. Chi-square tests and cox-regression was used to determine association between risk factors and mortality in the bivariate and multivariate analysis, respectively.
RESULTS: A total of 170 patients with UGIB were included. Males accounted for the majority (71.2%). Median age of the study population was 40.0 years. Chronic liver disease was present in 30.6% of study patients. The most common cause of UGIB among the 86 patients who underwent endoscopy was oesophageal varices (57%), followed by peptic ulcer disease (18%) and gastritis (10%). Mortality occurred in 57 patients (33.5%) and was significantly higher in patients with high white blood cell count (HR 2.45, p 0.011), raised serum alanine aminotransferase (HR 4.22, p 0.016), raised serum total bilirubin (HR 5.79, p 0.008) and lack of an endoscopic procedure done (HR 4.40, p <0.001). Rebleeding was reported in 12 patients (7.1%) and readmission due to UGIB in 4 patients (2.4%)
CONCLUSIONS: Oesophageal varices was the most common cause of UGIB. One-third of patients admitted with upper gastrointestinal bleeding died within 60 days of admission, signifying a high burden. Rebleeding and readmission rates were low. A high WBC count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy were independent predictors of mortality. These findings can be used to risk-stratify patients who may benefit from early and more aggressive management.

Entities:  

Keywords:  Upper gastrointestinal bleeding mortality Tanzania

Mesh:

Substances:

Year:  2017        PMID: 29262794      PMCID: PMC5738843          DOI: 10.1186/s12876-017-0712-8

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


Background

Upper Gastrointestinal Bleeding is defined as hemorrhage originating from anywhere between the esophagus and the ligament of Treitz [1]. It is one of the most common gastrointestinal emergencies, with an average mortality rate of 10% [2, 3]. Despite advances in the diagnosis and management of UGIB, the mortality rate has not changed significantly in the last 50 years [2-4]. Effective management requires use of a risk-stratification tool to categorise patients into low-risk and high-risk group, which can be used to guide treatment and follow up [3]. Many risk factors for mortality have been found from different studies. A number of risk scores have been developed also. The most frequently used risk scoring system is the Rockall score which was developed in 1996. This score assesses the risk of death following UGIB and incorporates the patient’s age, systolic blood pressure, heart rate, presence of other comorbidities and endoscopic findings [3]. Another frequently used scoring system is the Glasgow Blatchford Score [3]. Upper GI bleeding continues to be a significant cause of morbidity and mortality in Tanzania. For example, a one restrospective study enrolled 130 admitted patients with UGIB within two years [5]. Similarly, in another study in northern Tanzania, of all patients who underwent a fiberoptic upper GI endoscopy, 18.7% were found to have evidence of UGIB [6]. Oesophageal varices and peptic ulcer disease (PUD) being the most common causes in both these studies. Studies in Tanzania have shown a mortality rate ranging between 10 and 17% of patients admitted with UGIB [5-7]. This study was done at Muhimbili National Hospital (MNH) in Tanzania, which is the largest tertiary referral hospital currently in the country. No such studies had previously been done from this setting. Only one study was found that was prospectively done to find the risk factors of mortality among patients with UGIB. This study was aimed at identifying the causes of UGIB and risk factors for mortality in these patients, which would help better risk-stratify patients and guide management more efficiently, particularly in resource limited areas.

Methods

This was a prospective, cohort study where participants were recruited consecutively on admission from June 2015 to January 2016 and followed up for 60 days from admission. The study population were all patients admitted to MNH due to UGIB. MNH is one of the four tertiary hospitals in the country. It also serves as a tertiary level referral for three municipal hospitals in Dar es Salaam. MNH admits patients with upper gastrointestinal bleeding primarily at Mwaisela Ward, which serves as the Internal Medicine ward for the hospital. The hospital receives approximately 25 to 30 patients a month with acute upper gastrointestinal bleeding. The patients are initially seen at the Emergency Medicine Department of the hospital and are then shifted to the medical ward after stabilization, where they are then managed accordingly. Facility for upper gastrointestinal endoscopy is available during official work hours and is performed by trained endoscopists in the department of Gastroenterology. A target sample size of 100 patients was established based on sample size calculation with a confidence interval of 95%, a 5% margin of error and expected incidence of 10% [7].

Data collection process

All patients were entered into the study after an informed consent. Relevant data on demographics, medical history and comorbidities was collected on admission by interviewing the study participants or their guardians if the study participants were not able to answer. Admission vital signs from the Emergency Medicine Department (blood pressure, pulse rate, respiratory rate and oxygen saturation) were also recorded. Data on comorbidities was either confirmed by the patients themselves or through their records. Blood samples for laboratory tests were collected within 24 h of admission. Upper GI endoscopy was also done by trained personnel in the Gastroenterology Unit for those who could afford to pay for it in order to identify the cause and severity of the bleeding. (Approximately $60). All patients were then followed up while admitted in the ward, thereafter two-weekly follow-up was done after discharge up to 60 days post-initial admission or death. UGIB was defined as any acute episode of vomiting blood or passing melena stool in the 24 h prior to admission to the hospital. Rebleeding was defined as a separate episode of vomiting of fresh blood or melena, or nasogastric evidence of new bleeding after admission within the hospital or within 60 days post-admission. Encephalopathy was defined as having symptoms and signs consistent with central nervous system involvement. Chronic liver disease was defined by clinical criteria of stigmata of chronic liver disease with evidence of small liver span by clinical examination or ultrasound. Renal insufficiency was defined as having acute kidney injury and/or chronic kidney disease from any cause. All patients were treated according to standard treatment protocols of the hospital. Data was analyzed using SPSS 23 for analysis. Relevant frequencies and tables were generated for all variables. Proportions and medians/interquartile ranges were calculated for appropriate variables. The differences in median values of continuous variables between the outcome groups was determined statistically by use of Mann-Whitney U test. Incidence of mortality, rebleeding and readmission were calculated. All risk factors were analyzed to determine their association with mortality by use of the chi-square test. Relative Risk was used as a measure of association for factors associated with 60-day mortality. Cox-regression analysis was done to find out the independent risk of each categorical variable towards 60-day mortality. All factors with a p value of <0.05 in the bivariate analysis were included in the regression model. Missing indicator variable method was used to retain cases with missing data in the regression model. Statistical significance was set at p value <0.05.

Results

Etiology of upper GI bleeding

From the 170 study participants, 86 underwent endoscopy. The most common cause of UGIB in these patients was oesophageal varices (57.0%), followed by peptic ulcer disease (18.6%) and gastritis (10.4%) (See Fig. 1).
Fig. 1

Endoscopic etiologies of UGIB among 86 patients who underwent endoscopy

Endoscopic etiologies of UGIB among 86 patients who underwent endoscopy Patients who did not undergo endoscopy were more likely to have renal insufficiency (OR 3.30, 95% CI 1.31–8.33, p 0.009) and encephalopathy (OR 4.17, 95% CI 1.12–15.53, p 0.023) on admission. None of the patients with HIV infection underwent endoscopy (p 0.006).

Outcomes

Over a period of 60 days, 57 patients died (33.5%). Almost a quarter (24.6%) died in the first 24 h after admission, and almost half (49.1%) died within 72 h of admissions. Majority (96.5%) died in the first 30 days post-admission. Rebleeding was present in 12 patients (7.1%). A quarter (25.0%) rebled within the first 96 h of admission. Four patients were readmitted due to UGIB in the follow up period. All of them were readmitted after 30 days and before 60 days post-admission. Figures 2, 3, 4 and 5 show the Kaplan-Meier survival curves for the independent predictors of 60-day mortality. (See Figs. 2, 3, 4 and 5).
Fig. 2

Kaplan-Meier Survival Curve for 60-day mortality by Serum Total Bilirubin Levels

Fig. 3

Kaplan-Meier Survival Curve for 60-day mortality by Serum ALT Levels

Fig. 4

Kaplan-Meier Survival Curve for 60-day mortality by WBC Count

Fig. 5

Kaplan-Meier Survival Curve for 60-day mortality by Endoscopy Status

Kaplan-Meier Survival Curve for 60-day mortality by Serum Total Bilirubin Levels Kaplan-Meier Survival Curve for 60-day mortality by Serum ALT Levels Kaplan-Meier Survival Curve for 60-day mortality by WBC Count Kaplan-Meier Survival Curve for 60-day mortality by Endoscopy Status Patient population is described in Table 1. The association of mortality to different continuous variables (Table 2) and categorical variables (Table 3) revealed multiple significant associations. Factors that were significantly associated with mortality in univariate analysis (p < 0.05) were entered into the regression model for multivariate analysis as shown in Table 4.
Table 1

Clinical and Demographic Characteristics of Study Population

CharacteristicMedian (25–75) / Frequency
Age40.0 (31.0–56.3)
Sex
 Male121 (71.2%)
 Female49 (28.8%)
History of previous UGIB65 (38.2%)
Use of NSAIDs in previous one week7 (4.1%)
Comorbidity
 Any Comorbidity106 (62.4%)
 Cardiac Disease14 (8.2%)
 Renal Insufficiency26 (15.3%)
 Chronic Liver Disease52 (30.6%)
 Encephalopathy14 (8.2%)
 Malignancy16 (9.4%)
 Hypertension13 (7.6%)
 Diabetes Mellitus5 (2.9%)
 HIV7 (4.1%)
Smoking9 (5.3%)
Alcohol use in previous one week22 (12.9%)
Initial Vital Signs
 Systolic Blood Pressure (mmHg)113.5 (102.0–130.0)
 Diastolic Blood Pressure (mmHg)63.0 (56.8–80.3)
 Pulse Rate (beats/min)101.5 (86.0–108.3)
 Respiratory Rate (breaths/min)20.0 (19.0–23.0)
 Arterial Oxygen Saturation (%)100.0 (100.0–100.0)
Initial Laboratory Data
 White Blood Count (k/μl)8.1 (4.6–12.4)
 Hemoglobin (g/dL)6.2 (4.5–8.8)
 Platelets (k/μl)178.5 (90.8–293.3)
 Serum Creatinine (μmol/L)78.0 (63.5–150.5)
 Serum BUN (g/dL)6.5 (3.3–12.6)
 Serum ALT (U/L)23.0 (15.0–47.0)
 Serum AST (U/L)36.0 (22.0–93.0)
 Serum Total Bilirubin (μmol/L)12.7 (7.6–29.9)
 Prothrombin Time (seconds)12.5 (11.2–14.1)
 APTT (seconds)28.4 (25.2–32.8)
 INR1.1 (1.0–1.3)
Rockall Score
 Pre-Endoscopy3.0 (1.0–4.0)
 Post-Endoscopy6.0 (4.0–7.0)

A total 170 individuals were recruited in the study. The mean and median age of the study population was 44.9 and 40.0 years, respectively. Majority were males (71.2%) and 38.2% had a previous episode of UGIB (either hematemesis or melena). Chronic liver disease was the most common comorbidity present (30.6%). (See Table 1)

Table 2

Demographic and Clinical Predictors for 60-day Mortality (Continuous Variables)

Factor60-day Mortality p value
Yes(Median, 25–75)No(Median, 25–75)
Age45.0 (33.5–57.5)39.0 (31.0–55.5)0.168
Initial Vital Signs
 Systolic Blood Pressure (mmHg)114.0 (99.5–131.0)116.0 (103.0–130.0)0.513
 Diastolic Blood Pressure (mmHg)70.0 (57.5–82.5)67.0 (56.0–79.0)0.419
 Pulse Rate (beats/min)101.0 (91.0–113.0)97.0 (83.5–108.0)0.066
 Respiratory Rate (breaths/min)20.0 (19.0–23.0)20.0 (19.5–23.0)0.972
 Arterial Oxygen Saturation (%)100.0 (100.0–100.0)100.0 (100.0–100.0) 0.035
Initial Laboratory Data
 White Blood Count (k/μl)10.9 (7.7–16.7)6.7 (4.0–10.2) <0.001
 Hemoglobin (g/dL)7.4 (4.9–9.3)6.0 (4.4–8.2)0.058
 Platelets (k/μl)183.0 (133.0–278.0)172.5 (77.4–300.3)0.339
 Serum Creatinine (μmol/L)105.5 (72.3–289.2)69.4 (62.2–101.6) 0.001
 Serum BUN (g/dL)9.7 (4.7–23.4)4.5 (3.0–9.1) 0.001
 Serum ALT (U/L)58.0 (14.3–113.0)21.0 (15.0–35.0) 0.004
 Serum AST (U/L)74.0 (33.5–274.0)29.5 (18.0–50.8) <0.001
 Serum Total Bilirubin (μmol/L)83.5 (17.7–421.1)11.3 (7.0–17.6) 0.001
 Prothrombin Time (seconds)14.1 (12.7–19.4)12.1 (11.0–13.3) 0.002
 APTT (seconds)28.5 (24.9–37.5)28.4 (25.2–31.4)0.533
 INR1.3 (1.2–1.7)1.1 (1.0–1.2) 0.001
Rockall Score
 Pre-Endoscopy Rockall Score3.0 (2.0–4.0)3.0 (1.0–4.0)0.143
 Post-Endoscopy Rockall Score6.0 (5.0–7.0)6.0 (4.0–7.0)0.620

Comparison of medians of different continuous variables revealed that the following were all associated with a higher risk of mortality: A raised WBC, serum creatinine, serum BUN, serum ALT, serum AST, serum total bilirubin, prothrombin time and INR and reduced oxygen saturation on admission (p < 0.05). (See Table 2)

Table 3

Demographic and Clinical Predictors for 60-day Mortality (Categorical Variables)

Factor60-day MortalityRelative Risk(95% CI) P value
YesNoTotal
Age
  > 40 years31 (37.3%)52 (62.7%)831.250.303
  ≤ 40 years26 (29.9%)61 (70.1%)87(0.82–1.91)
Sex
 Male41 (33.9%)80 (66.1%)1211.040.878
 Female16 (32.7%)33 (67.3%)49(0.65–1.67)
History of previous UGIB
 Yes21 (27.6%)55 (72.4%)760.720.143
 No36 (38.3%)58 (61.7%)94(0.46–1.13)
Use of NSAIDs in previous one week
 Yes1 (14.3%)6 (85.7%)70.420.426
 No56 (34.4%)107 (65.6%)163(0.07–2.58)
Any Comorbidity
 Yes40 (37.7%)66 (62.3%)1061.420.135
 No17 (26.6%)47 (73.4%)64(0.88–2.29)
Cardiac Disease
 Yes6 (42.9%)8 (57.1%)141.310.556
 No51 (32.7%)105 (67.3%)156(0.69–2.50)
Renal Insufficiency
 Yes16 (61.5%)10 (38.5%)26 2.16 0.001
 No41 (28.5%)103 (71.5%)144 (1.45–3.22)
Chronic Liver Disease
 Yes21 (28.0%)54 (72.0%)750.740.175
 No36 (37.9%)59 (62.1%)95(0.47–1.15)
Encephalopathy
 Yes11 (78.6%)3 (21.4%)14 2.67 <0.001
 No46 (29.5%)110 (70.5%)156 (1.85–3.84)
Malignancy
 Yes9 (56.3%)7 (43.8%)16 1.81 0.043
 No48 (31.2%)106 (68.8%)154 (1.1–2.95)
Hypertension
 Yes6 (46.2%)7 (53.8%)131.420.364
 No51 (32.5%)106 (67.5%)157(0.76–2.67)
Diabetes Mellitus
 Yes4 (80.0%)1 (20.0%)5 2.49 0.044
 No53 (32.1%)112 (67.9%)165 (1.52–4.07)
HIV
 Yes5 (71.4%)2 (28.6%)7 2.24 0.043
 No52 (31.9%)111 (68.1%)163 (1.33–3.76)
Smoking
 Yes3 (33.3%)6 (66.7%)90.991.000
 No54 (33.5%)107 (66.5%)161(0.39–2.57)
Alcohol use in previous one week
 Yes8 (36.4%)14 (63.6%)221.100.763
 No49 (33.1%)99 (66.9%)148(0.60–2.00)
Systolic Blood Pressure
  < 110 mmHg23 (37.1%)39 (62.9%)621.180.455
  ≥ 110 mmHg34 (31.5%)74 (68.5%)108(0.77–1.81)
Diastolic Blood Pressure
  < 60 mmHg17 (31.5%)37 (68.5%)540.910.700
  ≥ 60 mmHg40 (34.5%)76 (65.5%)116(0.57–1.46)
Pulse Rate
  > 100 bpm30 (38.5%)48 (61.5%)781.310.210
  ≤ 100 bpm27 (29.3%)65 (70.7%)92(0.86–2.00)
Respiratory Rate
  > 18 bpm44 (32.6%)91 (67.4%)1350.880.611
  ≤ 18 bpm13 (37.1%)22 (62.9%)35(0.54–1.44)
Arterial Oxygen Saturation
  < 92%2 (50.0%)2 (50.0%)41.510.603
  ≥ 92%55 (33.1%)111 (66.9%)166(0.55–4.12)
White Blood Count (k/μl)
  > 11.0026 (54.2%)22 (45.8%)48 2.23 <0.001
  ≤ 11.0028 (24.3%)87 (75.7%)115 (1.47–3.37)
Hemoglobin (g/dL)
  < 10.0045 (31.7%)97 (68.3%)1420.740.310
  ≥ 10.009 (42.9%)12 (57.1%)21(0.43–1.28)
Platelets (k/μl)
  < 14018 (26.5%)50 (73.5%)680.690.115
  ≥ 14036 (38.3%)58 (61.7%)94(0.43–1.11)
Serum Creatinine (μmol/L)
  > 11521 (53.8%)18 (46.2%)39 2.20 0.001
  ≤ 11522 (24.4%)68 (75.6%)90 (1.38–3.51)
Serum BUN (g/dL)
  > 7.421 (47.7%)23 (52.3%)44 2.39 0.003
  ≤ 7.412 (20.0%)48 (80.0%)60 (1.32–4.32)
Serum ALT (U/L)
  > 5517 (73.9%)6 (26.1%)23 4.19 <0.001
  ≤ 5515 (17.6%)70 (82.4%)85 (2.49–7.04)
Serum AST (U/L)
  > 3424 (40.7%)35 (59.3%)59 2.35 0.007
  ≤ 349 (17.3%)43 (82.7%)52 (1.20–4.59)
Serum Total Bilirubin (μmol/L)
  > 20.513 (50.0%)13 (50.0%)26 5.00 <0.001
  ≤ 20.55 (10.0%)45 (90.0%)50 (2.0–12.50)
Prothrombin Time (seconds)
  > 12.113 (46.4%)15 (53.6%)28 3.71 0.008
  ≤ 12.13 (12.5%)21 (87.5%)24 (1.20–11.51)
APTT (seconds)
  > 30.47 (35.0%)13 (65.0%)201.080.842
  ≤ 30.411 (32.4%)23 (67.6%)34(0.50–2.34)
INR
  > 1.1313 (48.1%)14 (51.9%)27 4.17 0.004
  ≤ 1.133 (11.5%)23 (88.5%)26 (1.34–12.97)
Endoscopy
 Not Done46 (54.8%)38 (45.2%)84 4.28 <0.001
 Done11 (12.8%)75 (87.2%)86 (2.39–7.69)
Endoscopy Diagnosis
 Oesophageal Varices6 (12.2%)43 (87.8%)490.911.000
 Other Diagnosis5 (13.5%)32 (86.5%)37(0.30–2.74)
Pre-Endoscopy Rockall Score1.29
  > 321 (39.6%)32 (60.4%)53(0.84–1.98)0.257
  ≤ 336 (30.8%)81 (69.2%)117
Post-Endoscopy Rockall Score
  > 58 (15.1%)45 (84.9%)531.610.524
  ≤ 53 (9.4%)29 (90.6%)32(0.46–5.63)

Mortality was also compared to different categorical variables as outlined in Table 3. A high serum total bilirubin was associated with a 5-fold increased risk of mortality (RR = 5.00, p < 0.001). Patients with a raised serum ALT level (RR = 4.19, p < 0.001), a raised INR (RR = 4.17, p = 0.004), a prolonged prothrombin time (RR = 3.71, p = 0.008) and those who did not undergo endoscopy during admission (RR = 4.28, p < 0.001) had an almost 4-fold increased risk of mortality within 60 days from admission. Other factors that were associated with a higher risk of mortality included patients with renal insufficiency (RR = 2.16, p < 0.001), encephalopathy (RR = 2.67, p < 0.001), malignancy (RR = 1.81, p = 0.043), diabetes mellitus (RR = 2.49, p = 0.044), HIV disease (RR = 2.24, p = 0.043), a raised WBC count (RR = 2.23, p < 0.001), a raised serum creatinine level (RR = 2.20, p = 0.001), a raised serum BUN level (RR = 2.39, p = 0.003), and a raised serum AST level (RR = 2.35, p = 0.007). (See Table 3)

Table 4

Cox-Regression Analysis of Predictors for 60-day Mortality (Multivariate Analysis)

PredictorHazard Ratio (95% CI) P value
Renal Insufficiency1.38 (0.54–3.51)0.504
Encephalopathy1.19 (0.46–3.06)0.723
HIV0.58 (0.16–2.07)0.402
Diabetes Mellitus2.14 (0.54–8.50)0.279
Malignancy0.58 (0.21–1.64)0.303
White Blood Cell Count >11 k/μl 2.45 (1.23–4.89) 0.011
Serum Creatinine >115 μmol/L1.55 (0.57–4.23)0.896
Serum BUN >7.4 g/dL1.46 (0.55–3.85)0.445
Serum ALT >55 U/L 4.22 (1.31–13.57) 0.016
Serum AST > 34 U/L1.11 (0.39–3.17)0.843
Serum Total Bilirubin >20.5 μmol/L 5.79 (1.58–21.25) 0.008
Prothrombin Time > 12.1 s0.33 (0.01–21.14)0.598
INR > 1.138.57 (0.14–536.04)0.309
Endoscopy Not Done 4.40 (2.11–9.17) <0.001

Multivariate analysis to identify independent predictors of 60-day mortality was done using Cox-Regression analysis. Factors that were shown to be significantly associated with a higher risk of 60-day mortality by bivariate analysis were included in the regression model. Multivariate analysis showed that a higher WBC count of >11 k/μl, a high serum ALT >55 U/L, a high serum total bilirubin >20.5 μmol/L were independently associated with an increased risk of mortality. Patients who did not undergo endoscopy had a 4.4 times higher rate of death within 60 days of admission (Table 4)

Clinical and Demographic Characteristics of Study Population A total 170 individuals were recruited in the study. The mean and median age of the study population was 44.9 and 40.0 years, respectively. Majority were males (71.2%) and 38.2% had a previous episode of UGIB (either hematemesis or melena). Chronic liver disease was the most common comorbidity present (30.6%). (See Table 1) Demographic and Clinical Predictors for 60-day Mortality (Continuous Variables) Comparison of medians of different continuous variables revealed that the following were all associated with a higher risk of mortality: A raised WBC, serum creatinine, serum BUN, serum ALT, serum AST, serum total bilirubin, prothrombin time and INR and reduced oxygen saturation on admission (p < 0.05). (See Table 2) Demographic and Clinical Predictors for 60-day Mortality (Categorical Variables) Mortality was also compared to different categorical variables as outlined in Table 3. A high serum total bilirubin was associated with a 5-fold increased risk of mortality (RR = 5.00, p < 0.001). Patients with a raised serum ALT level (RR = 4.19, p < 0.001), a raised INR (RR = 4.17, p = 0.004), a prolonged prothrombin time (RR = 3.71, p = 0.008) and those who did not undergo endoscopy during admission (RR = 4.28, p < 0.001) had an almost 4-fold increased risk of mortality within 60 days from admission. Other factors that were associated with a higher risk of mortality included patients with renal insufficiency (RR = 2.16, p < 0.001), encephalopathy (RR = 2.67, p < 0.001), malignancy (RR = 1.81, p = 0.043), diabetes mellitus (RR = 2.49, p = 0.044), HIV disease (RR = 2.24, p = 0.043), a raised WBC count (RR = 2.23, p < 0.001), a raised serum creatinine level (RR = 2.20, p = 0.001), a raised serum BUN level (RR = 2.39, p = 0.003), and a raised serum AST level (RR = 2.35, p = 0.007). (See Table 3) Cox-Regression Analysis of Predictors for 60-day Mortality (Multivariate Analysis) Multivariate analysis to identify independent predictors of 60-day mortality was done using Cox-Regression analysis. Factors that were shown to be significantly associated with a higher risk of 60-day mortality by bivariate analysis were included in the regression model. Multivariate analysis showed that a higher WBC count of >11 k/μl, a high serum ALT >55 U/L, a high serum total bilirubin >20.5 μmol/L were independently associated with an increased risk of mortality. Patients who did not undergo endoscopy had a 4.4 times higher rate of death within 60 days of admission (Table 4)

Discussion

This prospective, cohort study aimed at identifying the major causes of upper gastrointestinal bleeding and the magnitude of mortality, rebleeding and readmission and their risk factors in a tertiary level hospital in Tanzania. The most common cause of upper GI bleeding in this study group was oesophageal varices, found in 57% of patients. PUD accounted for 18% of cases (equally distributed among duodenal and gastric ulcer). The high prevalence of oesophageal varices has also been found in studies done in other regions of Tanzania such as Moshi [5] and Mwanza [6, 7]. In contrast, PUD was the most common cause of UGIB in studies done in Korea [8], USA [9] and various European countries [3, 10]. Oesophageal varices are most often a result of portal hypertension. Schistosomiasis and chronic liver disease are among the most common causes of portal hypertension in sub-Saharan Africa. The prevalence of chronic liver disease is similar to studies done in Romania [3, 4]. However, this prevalence is higher than those found in studies in Mwanza [6, 7], Europe [11] and Korea [8, 12]. One reason for this could be the type of patients involved in this study. The study was conducted in a tertiary referral center, hence it admits patients with the most severe forms of disease. Secondly, although not directly tested, the high prevalence of schistosomiasis and chronic hepatitis B infection in this setting may have contributed to the high prevalence of chronic liver disease. More than 90% of cases of schistosomiasis occur in sub-Saharan Africa and Tanzania is the second highest in terms of burden of disease in this region [13]. The estimated country prevalence of schistosomiasis is 51.5% [13]. One study done in Mwanza showed a high rate of active schistosome infection in adults presenting with hematemesis [7]. Similarly, one study found a 12.4% positivity of S. mansoni in stool samples [14] Studies in Tanzania have shown a prevalence of chronic hepatitis B infection ranging from 2.9–7.0% [15-17]. PUD was the second most common diagnosis. It is well known that PUD is associated with H. pylori infection. Studies done in Tanzania have shown a prevalence of H. pylori to be more than 85% in the population [18-20]. The prevalence was shown to increase with age [19]. The overall mortality rate within 60 days of admission was 33.5%. This is very high compared to the overall mortality rate from upper GI bleeding worldwide [2]. Many studies looking at mortality rates among patients with upper GI bleeding have shown mortality rates ranging from 1 to 20% [3, 6, 7, 9, 21–24]. A few studies have mortality rates higher than 30% [10, 25, 26]. The high mortality rate in this study could be due to delayed or more severe presentation to a referral center, thus increasing the likelihood of mortality due to delay or failure in achieving hemodynamic stability, particularly in the absence of urgent endoscopic intervention. Furthermore, there is a general lack of available intervention measures such as blood transfusion and urgent endoscopic intervention and this may have contributed to the high mortality. It is noteworthy that almost half of the patients died within 72 h of admission to the hospital, suggesting the importance of early intervention as the key in the management of patients with acute UGIB. A high WBC count was associated with almost 2.5 times higher rate of death compared to patients with a normal WBC count on admission. A high WBC has been associated with mortality in other studies too [27-29]. Leukocytosis is a marker for inflammation and infection, but it also occurs in other situations like trauma, exercise, drug therapy with steroids, malignancy, poisoning, psychosis and diabetic ketoacidosis. Circulating catecholamines may also lead to leukocytosis. It has been speculated that leukocytosis may represent an acute phase marker [30]. One study on upper GI bleeding patients revealed that a high WBC count was associated with more severe presentation and disease course, although it was not associated with a higher risk of mortality. The authors used a lower cut-off value of high WBC (8.5 k/μl) [31] Several studies have shown the association between leukocytosis and higher risk of mortality in various conditions [32-34]. It is possible that some underlying infection or inflammatory condition contributed to the mortality in these patients. Patients admitted with elevated ALT had about 4 times higher rate of death within 60 days compared to patients admitted with normal levels of ALT. Abnormal liver enzymes, particularly a raised ALT has been shown to be a risk factor for mortality in different studies [3, 24, 35, 36]. ALT levels can be raised in patients with myocardial infarction and with ischemia to the liver [37]. Although these were not measured directly, it is possible that more severe bleeding was associated with ischemia to the heart and liver, thus contributing to the higher mortality. Higher levels of ALT have also been associated with obesity, serum cholesterol and underlying unrecognized liver diseases [37, 38]. It may be possible that these comorbidities may have contributed to mortality in this group of patients. A high serum total bilirubin during admission was associated with an almost 6 times increased rate of death in this study population. Other studies have also shown this association between high serum total bilirubin and mortality [21, 22, 25, 31, 36, 39, 40]. High levels of serum total bilirubin have been associated with all-cause mortality [41, 42]. The exact mechanism is unclear. It has been shown in different studies that a high level of serum total bilirubin is associated with cardiovascular disease, particularly ischemic heart disease [43] and acute myocardial infarction [44]. The increased risk of acute cardiovascular events in patients with high serum total bilirubin may have contributed to the increased mortality rate in this study group. Patients who did not undergo endoscopy during their hospital stay had about 4 times a higher rate of death within 60 days compared to patients who had an endoscopy done. Lack of endoscopy was shown to be a risk factor for mortality in another study done in Bugando [7]. It may be possible that patients who were hemodynamically unstable and very sick overall on admission did not undergo endoscopy and were at higher risk of mortality, as seen by the fact that patients with renal insufficiency, HIV and encephalopathy were all less likely to undergo endoscopy. Consensus guidelines outline the importance of endoscopy in acute upper GI bleeding. It helps to identify the source of bleeding, provide prognostic information regarding the risk of bleeding, and offer therapy for hemostasis [45]. One study also showed reduced incidence of myocardial infarction and overall mortality in patients who received initial resuscitation (including endoscopic intervention) [46] Hence, the patients who did not undergo endoscopy may have missed the chance to be offered endoscopic intervention because of a lack of diagnosis and this may be the reason for the increased mortality rate in this group of patients. The strength of this study was that it was a prospective study where many variables that could potentially predict adverse outcomes were assessed. Furthermore, all patients were followed-up in this study. The study had some limitations. Half of the patients did not undergo endoscopy due to not being able to afford it. This may have underestimated the burden of some etiologies. Importantly, not undergoing endoscopy was an independent predictor of mortality. Therefore, more serious etiologies may have been missed which led to early death. Some laboratory values were not obtained for some patients and this may have underestimated or overestimated the significance of these factors with the outcomes. Presence of comorbidities was assessed by patient interview or clinical diagnosis. True melena was ascertained verbally only. This may have included some patients who had black stool from ingestion of previously prescribed ferrous sulphate. Gold standard criteria for diagnosis of comorbidities were not used in all patients. This study identified an important area in the local country but the results may not necessarily be generalisable to settings with different epidemiological disease patterns, particularly for chronic liver disease. Subgroup analysis to identify specific risk factors for mortality following variceal bleeding and ulcer bleeding could not be done due to small sample size these subgroups would have.

Conclusions

Oesophageal varices was the most common cause of UGIB, followed by peptic ulcer disease. There was a high burden of mortality in this study, about one-third of patients admitted with UGIB died within 60 days. Rebleeding and readmission rates were low. Independent predictors of 60-day mortality were a high WBC count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy. It is recommended that patients require early and more aggressive intervention in acute UGIB and possibly larger studies can be conducted looking at other factors that may contribute to mortality in UGIB patients. It is also important to study the reasons for a lack of endoscopy among patients with UGIB since this is a potentially correctable factor which can then lead to reduction in mortality and improvement on clinical care of these patients in the country.
  45 in total

1.  Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.

Authors:  C P Cannon; C H McCabe; R G Wilcox; J H Bentley; E Braunwald
Journal:  Am J Cardiol       Date:  2001-03-01       Impact factor: 2.778

2.  Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe.

Authors:  A Lanas; L Aabakken; J Fonseca; Z A Mungan; G V Papatheodoridis; H Piessevaux; L Cipolletta; J Nuevo; M Tafalla
Journal:  Aliment Pharmacol Ther       Date:  2011-04-11       Impact factor: 8.171

3.  Serum bilirubin and risk of ischemic heart disease in middle-aged British men.

Authors:  L H Breimer; G Wannamethee; S Ebrahim; A G Shaper
Journal:  Clin Chem       Date:  1995-10       Impact factor: 8.327

4.  The prevalence and significance of leukocytosis in upper gastrointestinal bleeding.

Authors:  N Chalasani; K Patel; W S Clark; C M Wilcox
Journal:  Am J Med Sci       Date:  1998-04       Impact factor: 2.378

5.  Association of serum bilirubin with aging and mortality.

Authors:  Brigid S Boland; Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  J Clin Exp Hepatol       Date:  2014-01-20

6.  Predictors of mortality in patients admitted to hospital for acute upper gastrointestinal hemorrhage.

Authors:  J Zimmerman; J Siguencia; E Tsvang; R Beeri; R Arnon
Journal:  Scand J Gastroenterol       Date:  1995-04       Impact factor: 2.423

7.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17

8.  Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding.

Authors:  Alan Barkun; Marc Bardou; John K Marshall
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

9.  Prevalence of hepatitis B virus infection among health care workers in a tertiary hospital in Tanzania.

Authors:  A Mueller; L Stoetter; S Kalluvya; A Stich; C Majinge; B Weissbrich; C Kasang
Journal:  BMC Infect Dis       Date:  2015-09-23       Impact factor: 3.090

Review 10.  Alanine aminotransferase-old biomarker and new concept: a review.

Authors:  Zhengtao Liu; Shuping Que; Jing Xu; Tao Peng
Journal:  Int J Med Sci       Date:  2014-06-26       Impact factor: 3.738

View more
  13 in total

1.  Clinical mortality risk factors of variceal upper gastrointestinal bleeding in a Malagasy surgical intensive care unit.

Authors:  Aurélia Rakotondrainibe; Nadia M P Rahanitriniaina; Harifetra M R Randriamizao; Jasper G Raelison; Rado M Ramanampamonjy; Andriambelo T Rajaonera; François Sztark
Journal:  Afr J Emerg Med       Date:  2020-07-21

2.  Praziquantel and Upper Gastrointestinal Bleeding in Hepatic Schistosomiasis: A Quasi-Experimental Study.

Authors:  Christopher Kenneth Opio; Francis Kazibwe; Narcis B Kabatereine; Lalitha Rejani; Ponsiano Ocama
Journal:  Drugs Real World Outcomes       Date:  2020-12-26

3.  Deciphering the Mechanical Network of Chronic Atrophic Gastritis: A Urinary Time-Dependent Metabonomics-Based Network Pharmacology Study.

Authors:  YueTao Liu; WenQian Xu; XueMei Qin
Journal:  Front Physiol       Date:  2019-08-06       Impact factor: 4.566

4.  The diagnostic accuracy of routine clinical findings for detection of esophageal varices in rural sub-Saharan Africa where schistosomiasis is endemic.

Authors:  Christopher K Opio; Lalitha Rejani; Francis Kazibwe; Ponsiano Ocama
Journal:  Afr Health Sci       Date:  2019-12       Impact factor: 0.927

5.  Interventional Algorithm in Gastrointestinal Bleeding-An Expert Consensus Multimodal Approach Based on a Multidisciplinary Team.

Authors:  Anabela Rodrigues; Alexandre Carrilho; Nuno Almeida; Cilénia Baldaia; Ângela Alves; Manuela Gomes; Luciana Gonçalves; António Robalo Nunes; Carla Leal Pereira; Mário Jorge Silva; José Aguiar; Rosário Orfão; Pedro Duarte; Rui Tato Marinho
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  A Protocol for a Systematic Review and Meta-Analysis of Hospital Readmissions Following Acute Upper Gastrointestinal Bleeding.

Authors:  Sandeep Kaur; Cody L Dunne; Lauren Bresee
Journal:  Cureus       Date:  2021-11-04

7.  Older age and diclofenac are associated with increased risk of upper gastrointestinal bleeding in gout patients.

Authors:  Wan Syamimee Wan Ghazali; Wan Mohd Khairul Bin Wan Zainudin; Nurul Khaiza Yahya; Asmahan Mohamed Ismail; Kah Keng Wong
Journal:  PeerJ       Date:  2021-05-20       Impact factor: 2.984

8.  The magnitude and correlates of esophageal Varices among newly diagnosed cirrhotic patients undergoing screening fibre optic endoscope before incident bleeding in North-Western Tanzania; a cross-sectional study.

Authors:  Daniel W Gunda; Semvua B Kilonzo; Zakhia Mamballah; Paulina M Manyiri; David C Majinge; Hyasinta Jaka; Benson R Kidenya; Humphrey D Mazigo
Journal:  BMC Gastroenterol       Date:  2019-11-29       Impact factor: 3.067

9.  Profile and outcome of patients with upper gastrointestinal bleeding presenting to urban emergency departments of tertiary hospitals in Tanzania.

Authors:  Shaffin S Rajan; Hendry R Sawe; Asha J Iyullu; Dereck A Kaale; Nancy A Olambo; Juma A Mfinanga; Ellen J Weber
Journal:  BMC Gastroenterol       Date:  2019-12-10       Impact factor: 3.067

10.  The risk factors for the recurrent upper gastrointestinal hemorrhage among acute peptic ulcer disease patients in Syria: A prospective cohort study.

Authors:  Sara Mona Bitar; Maen Moussa
Journal:  Ann Med Surg (Lond)       Date:  2022-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.